Your Directors are pleased to present their 51^st Annual Report on the business and operations together with the Audited
Financial Statements of the Company for financial year ended 31 March, 2025. Consolidated performance of the Company
and its subsidiaries has been referred to, wherever required.

FINANCIAL PERFORMANCE

OVERVIEW OF FINANCIAL PERFORMANCE

During financial year ended 31 March, 2025, the Company's total revenue including other income was C93,205.0 Million on
Standalone basis as against C82,698.4 Million achieved in the previous year, registering a growth of 12.7%.

The export turnover of the Company during financial year 2024-25 was C24,908.3 Million as against C19,301.8 Million achieved
in the previous year, registering a growth of 29.0%.

During financial year ended 31 March, 2025, the Company
and its subsidiaries achieved a total revenue including
other income of C1,34,582.6 Million on Consolidated basis,
as against a turnover of C1,29,784.2 Million achieved in the
previous year, registering a growth of 3.7 %.

During financial year ended 31 March, 2025, Standalone
Profit before interest, depreciation and tax from continuing
operations increased by 39.2% at C26,632.6 Million as against
C19,133.4 Million in the previous year, whereas Consolidated
Profit before interest, depreciation and tax increased by
23.5% at C30,058.9 Million as against C24,348.4 Million in
the previous year. As a result, Standalone Profit before tax
from continuing operations increased by 44.5% over the
previous year to C23,035.4 Million and Consolidated Profit
before tax was C25,270.3 Million, which grew by 24.9% over
the previous year.

The Standalone Net Profit after tax from continuing
operations for financial year ended 31 March, 2025 increased
by 33.9% to C20,897.2 Million over the previous year while the
Consolidated Net Profit after tax increased by 20.6% over the
previous year to C21,654.8 Million.

DIVIDEND

During financial year 2024-25, the Board of Directors on
07 February, 2025, declared and paid an interim dividend
of C37/- / (Rupees Thirty Seven only) per equity share of
C2/- (Rupees Two only) each, being 1850% of paid up share
capital of the Company. In addition, your Directors are
pleased to recommend payment of C8 /- (Rupees Eight only)
per equity share of C2/- (Rupees Two only) each as final
dividend for financial year 2024-25, for the approval of the
Members at the ensuing Annual General Meeting (AGM) of
the Company. If approved, the total dividend (interim and
final) for financial year 2024-25 will be C45 /- (Rupees Forty
Five only) per equity share of C2/- (Rupees Two only) each
as against the total dividend of C40/- (Rupees Forty only)
per equity share of C2/- (Rupees Two only) each paid for the
previous financial year.

In compliance with the requirement of Regulation 43A of
the SEBI (Listing Obligation and Disclosure Requirements)
Regulations, 2015 (hereinafter referred to as “SEBI LODR
Regulations”), the Company has formulated its Dividend
Distribution Policy, which is available on the Company's website
at https://admin.alkemlabs.com/uploads/977928327
Dividend distribution policy 6b026313dc.pdf

The said Policy is also annexed to this Report as Annexure A.

TRANSFER TO RESERVES

The Company has not transferred any amount to the General
Reserve for financial year 2024-25.

SHARE CAPITAL

The paid up equity share capital of the Company as on
31 March, 2025 was C239.1 Million. The Company has
neither issued shares with differential rights as to dividend,
voting or otherwise nor issued shares to the Employees or
Directors of the Company, under any scheme (including sweat
equity shares).

DEPOSITS

The Company has not accepted any deposits from the public/
members during the year under review and accordingly no
amount on account of principal or interest on public deposits
was outstanding as on 31 March, 2025.

SUBSIDIARIES

As on 31 March, 2025, the Company has a total of 29
subsidiaries and 2 associate companies within the meaning
of Sections 2(87) and 2(6) of the Companies Act, 2013
(hereinafter referred to as “the Act”) respectively. The
Company does not have any joint venture company(ies).

During the year under review:

• M/s. Alixer Nexgen Therapeutics Limited was incorporated
as a wholly owned subsidiary of the Company in India, on
12 July, 2024;

• M/s. Alkem Wellness Limited was incorporated as a
wholly owned subsidiary of the Company in India, on
16 September, 2024;

• M/s. Pharmacor SpA was incorporated as a step-down
subsidiary of the Company in Chile, on 22 November, 2024;

• M/s. HaystackAnalytics Private Limited was classified as
an associate of the Company w.e.f. 10 January, 2025; and

• M/s. Sunsure Solarpark Twenty-Two Private Limited
was classified as an associate of the Company w.e.f.
29 January, 2025.

and none of the companies ceased to be a subsidiary of
the Company.

In addition to the above, the Company has also:

• Acquired 100% stake of M/s. Bombay Ortho Industries
Private Limited through M/s. Alkem Medtech Private
Limited, thereby making it a wholly owned step-down
subsidiary of the Company w.e.f. 16 April, 2025; and

• Acquired 100% stake of M/s. Adroit Biomed Limited,
thereby making it a wholly owned subsidiary of the
Company w.e.f, 23 April, 2025.

Pursuant to the first proviso to Section 129(3) of the Act and
Rule 5 and Rule 8(1) of the Companies (Accounts) Rules, 2014,
the salient features of financial statements, performance and
financial position of each subsidiary is given in Form AOC-1
as Annexure B to this Report.

The Audited Financial Statements of the subsidiaries
are available on the Company's website at https://www.
alhemlabs.com/investors/subsidiaru-accounts pursuant to
Section 136 of the Act.

MANAGEMENT DISCUSSION AND ANALYSIS

A detailed report on the Management Discussion and Analysis
is provided as a separate section forming part of this Report.

CORPORATE GOVERNANCE

In compliance with Regulation 34 read with Schedule V of the
SEBI LODR Regulations, a Report on Corporate Governance for
the year under review is provided as a separate section along
with a certificate from the Statutory Auditors conforming
the Company's compliance with the conditions of Corporate
Governance, forming part of this Report.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY
REPORT

In compliance with Regulation 34 of SEBI LODR Regulations, the
Business Responsibility and Sustainability Report, describing
the initiatives taken by the Company from an environmental,
social and governance perspective, is provided as a separate
section forming part of this Report.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

The Company undertakes CSR activities in accordance with
the Company's CSR Policy. The CSR program aims to address
the immediate and long term needs of the community and
focus on where the major impact on marginalized sections of
the society can be made. The Company's CSR strategy involves
a multi-sectoral inclusive approach to focus on community
needs. It strives to improve the well-being of communities
by focusing on key thematic areas of healthcare, education,
rural development, environment and sports. The Company
implements these activities directly or through reliable
partnerships with various NGOs. During financial year 2024¬
25, the Company has addressed the requirements of local
communities in the vicinity of its head office, manufacturing
facilities and R&D centers through focused projects in the
said thematic areas.

Details about the Company's CSR Policy and initiatives/
activities undertaken by the Company during financial year
2024-25 are outlined in the Report on CSR activities annexed
to this Report as Annexure C.

The CSR Policy is posted on Company's website: https://
a.d.min.a.l.kemla.bs.com/uploa.d.s/csr policy e0e5ec8d61.pdf

DIRECTORS AND KEY MANAGERIAL PERSONNEL

Appointments:

The details of the appointment during the year under review
is as follows:

Appointment of Mr. Rajeev Kher as an Independent Director
of the Company.

Considering the experience, expertise, proficiency and
high standards of integrity possessed by Mr. Rajeev Kher
(DIN: 01192524), the Board of Directors of the Company based
on recommendation of the Nomination and Remuneration
Committee, approved the appointment of Mr. Rajeev Kher
(DIN: 01192524) as an Additional Director until such time
that the approval of the Members of the Company has been
obtained, to hold office for a term of 5 (five) consecutive
years w.e.f. 09 August, 2024 upto 08 August, 2029.
The Members of the Company through Postal Ballot on
03 October, 2024, approved the said appointment of Mr. Rajeev
Kher as an Independent Director of the Company, not liable
to retire by rotation, for a term of 5 (five) consecutive years
w.e.f. 09 August, 2024 upto 08 August, 2029.

The details of appointments, post closure of the year under
review are as follows:

Appointment of Mr. Ranjal Laxmana Shenoy as an Additional
Director designated as an Independent Director of the
Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and high
standards of integrity possessed by Mr. Ranjal Laxmana
Shenoy (DIN: 00074761), the Board of Directors of the
Company based on recommendation of the Nomination
and Remuneration Committee and subject to approval of
the Members of the Company, approved the appointment
of Mr. Ranjal Laxmana Shenoy (DIN: 00074761) as an
Additional Director designated as an Independent Director of
the Company, to hold office for a term of 5 (five) consecutive
years w.e.f. 13 July, 2025 upto 12 July, 2030, not liable to
retire by rotation.

Appointment of Ms. Neela Bhattacherjee as an Additional
Director designated as an Independent Director of the
Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and
high standards of integrity possessed by Ms. Neela
Bhattacherjee (DIN: 01912483), the Board of Directors of
the Company based on recommendation of the Nomination
and Remuneration Committee and subject to approval of
the Members of the Company, approved the appointment of
Ms. Neela Bhattacherjee (DIN: 01912483) as an Additional
Director designated as an Independent Director of the
Company, to hold office for a term of 5 (five) consecutive
years w.e.f. 13 July, 2025 upto 12 July, 2030, not liable to
retire by rotation.

Resignation / Completion of tenure
Resignation

Dr. Dheeraj Sharma, Independent Director of the Company,
resigned w.e.f. 14 June, 2024 due to pre-occupation. The
Directors placed on record appreciation for the valuable
contribution made by Dr. Dheeraj Sharma during his tenure
as an Independent Director in the Company.

Completion of Tenure

Mr. Arun Kumar Purwar, Ms. Sudha Ravi and Ms. Sangeeta
Singh, Independent Directors of the Company shall be
completing their tenure of two consecutive terms of 5 years
each, as Independent Directors on the Board of Directors of
the Company on 12 July, 2025.

Directors liable to retire by rotation

Mr. Srinivas Singh (DIN: 06744441) and Mr. Mritunjay Kumar
Singh (DIN: 00881412) are liable to retire by rotation at the
ensuing AGM of the Company pursuant to the provisions of
Section 152 of the Act read with the Companies (Appointment
and Qualification of Directors) Rules, 2014 and the Articles
of Association of the Company and being eligible they
have offered themselves for re-appointment, on the
recommendation of the Nomination and Remuneration
Committee and the Board of Directors of the Company.

Particulars in pursuance of Regulation 36 of the SEBI LODR
Regulations read with Secretarial Standard - 2 on General
Meetings relating to Mr. Srinivas Singh and Mr. Mritunjay
Kumar Singh are included in the Notice of AGM.

Key Managerial Personnel

In accordance with the provisions of Section 203 of the Act
read with the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014 the following are the Key
Managerial Personnel of the Company as on 31 March, 2025:

• Mr. Sandeep Singh - Managing Director;

• Dr. Vikas Gupta - Chief Executive Officer;

• Mr. Nitin Agrawal - President and Chief Financial
Officer; and

• Mr. Manish Narang, President - Legal, Company Secretary
and Compliance Officer

Independent Directors

The Independent Directors hold office for a term of 5 (five)
years and are not liable to retire by rotation. The Independent
Directors of the Company fulfill the conditions specified in
the Act and SEBI LODR Regulations and are independent of
the management.

Declaration of independence from Independent
Directors

The Company has received declarations from all the
Independent Directors confirming that they meet the criteria
of independence as prescribed under the provisions of the
Act, read with the schedules and rules issued thereunder,
as well as Regulation 16(1)(b) of the SEBI LODR Regulations
(including any statutory modification(s) or re-enactment(s)
thereof for the time being in force). In terms of Regulation
25(8) of the SEBI LODR Regulations, the Independent Directors
have confirmed that they are not aware of any circumstance
or situation, which exist or may be reasonably anticipated,
that could impair or impact their ability to discharge their
duties with an objective independent judgement and without
any external influence.

The terms and conditions of appointment of the Independent
Directors are posted on Company's website:

https://admin.alkemlabs.com/uploads/Terms of
appointment Independent Directors 2a82f9dd72.pdf

Familiarization Program

In compliance with the requirements of SEBI LODR
Regulations, the Company has put in place a framework for
Directors' Familiarization Programme to familiarize them
with their roles, rights and responsibilities as Directors, the
working of the Company, nature of the industry in which
the Company operates, business model, etc. The details of
the Familiarization Programme conducted during financial
year under review are provided in the Corporate Governance
Report. The same is also available on the Company's
website at https://www.alkemlabs.com/investors/details-
familiarization-program.

Annual Evaluation of Board's Performance

The details of the annual evaluation of the Individual Directors,
Board as a whole and all the Committees of the Board have
been provided in the Corporate Governance Report, which
forms part of this Report.

The Independent Directors, at a separate meeting held on
18 March, 2025 evaluated performance of Non-Independent
Directors, performance of the Board as a whole and
performance of the Chairperson of the Company.

The evaluation of the Independent Directors was carried out
by the entire Board of Directors without the participation of
the respective Independent Director.

The Company follows a policy for selection and appointment
of Directors, Senior Management and their remuneration,
which is available on the Company's website at https://admin.
alkemlabs.com/uploads/1378936118 Nomination and
Remuneration Policy modified 27052016 307d64b304.
pdf. The said Policy is annexed to this Report as Annexure D.

PARTICULARS OF EMPLOYEES AND RELATED
DISCLOSURES

The disclosure pertaining to remuneration and other details
as required under Section 197(12) of the Act read with Rule
5(1) of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014 is annexed to this Report
as Annexure E.

Further, a statement showing the names and other particulars
of top ten employees in terms of remuneration drawn and
of employees drawing remuneration in excess of the limits
required under Section 197(12) of the Act read with Rule 5(2)
and 5(3) of the Companies (Appointment and Remuneration
of Managerial Personnel) Rules, 2014 forms part of this
Report. However, in terms of first proviso to Section 136(1) of
the Act, the Annual Report and Annual Financial Statements
are being sent by email to the Members and others entitled

thereto, excluding the aforesaid information. The said
information shall be provided electronically to any Member
on a written request to the Company Secretary to obtain a
copy of the same.

NUMBER OF MEETINGS OF THE BOARD

The Board of Directors met 5 (five) times during financial
year 2024-25. The details of the Board meetings and the
attendance of Directors thereat are provided in the Corporate
Governance Report, which forms part of this Report.

COMMITTEES OF THE BOARD

Audit Committee

The Audit Committee comprises of Mr. Arun Kumar Purwar
as Chairperson and Mr. Sandeep Singh, Mr. Mritunjay Kumar
Singh, Ms. Sangeeta Singh, Mr. Narendra Kumar Aneja and
Ms. Sudha Ravi as Members.

The brief terms of reference of the Audit Committee and the
particulars of meetings held and attendance thereat are
mentioned in the Corporate Governance Report which forms
part of this Report.

Nomination and Remuneration Committee

The Nomination and Remuneration Committee comprises
of Mr. Arun Kumar Purwar as Chairperson and Mr. Basudeo
N. Singh, Ms. Sudha Ravi and Mr. Narendra Kumar Aneja
as Members.

The brief terms of reference of the Nomination and
Remuneration Committee and the particulars of meetings
held and attendance thereat are mentioned in the Corporate
Governance Report which forms part of this Report.

Corporate Social Responsibility and Sustainability
Committee

The Board of Directors at its meeting held on 07 February,
2025 had renamed the ‘Corporate Social Responsibility
Committee' as the ‘Corporate Social Responsibility and
Sustainability Committee'.

The Corporate Social Responsibility and Sustainability
Committee comprises of Mrs. Madhurima Singh as
Chairperson and Mr. Sandeep Singh, Mr. Srinivas Singh,
Ms. Sangeeta Singh and Ms. Sudha Ravi as Members.

The brief terms of reference of the Corporate Social
Responsibility and Sustainability Committee and the
particulars of meetings held and attendance thereat are
mentioned in the Corporate Governance Report which forms
part of this Report.

Stakeholders' Relationship Committee

The Stakeholders' Relationship Committee comprises
of Mr. Sujjain Talwar as Chairperson and Mr. Mritunjay
Kumar Singh, Mrs. Madhurima Singh and Mr. Srinivas Singh
as Members.

The brief terms of reference of the Stakeholders'
Relationship Committee and the particulars of meetings
held and attendance thereat are mentioned in the Corporate
Governance Report which forms part of this Report.

Risk Management Committee

The Risk Management Committee comprises of Mr. Mritunjay
Kumar Singh as Chairperson and Mr. Sandeep Singh,
Mr. Srinivas Singh, Ms. Sudha Ravi, Mr. Narendra Kumar
Aneja and Mr. Sujjain Talwar as Members.

The brief terms of reference of the Risk Management
Committee and the particulars of meeting held and attendance
thereat are mentioned in the Corporate Governance Report
which forms part of this Report.

RISK MANAGEMENT

The Company's Board of Directors has overall responsibility
for the establishment and oversight of the Company's
risk management framework. The Company has a Board
approved Risk Management Policy. The Board of Directors
have constituted a Risk Management Committee which
is delegated with the responsibility of overseeing various
strategic, operational and financial risks that the organization
faces, along with assessment of risks, their management
and mitigation procedures. A detailed analysis of the
business risks and opportunities is given under Management
Discussion and Analysis Report forming part of this Report.

DIRECTORS’ RESPONSIBILITY STATEMENT

To the best of their knowledge and belief, your Directors
confirm that:

(a) in the preparation of the annual accounts for financial
year ended 31 March, 2025, the applicable accounting
standards have been followed along with proper
explanation relating to material departures, if any;

(b) they have selected such accounting policies and
applied them consistently and made judgements and
estimates that are reasonable and prudent so as to
give a true and fair view of the state of affairs of the
Company as at 31 March, 2025 and of the profit of the
Company for the year ended on that date;

(c) they have taken proper and sufficient care for
the maintenance of adequate accounting records
in accordance with the provisions of the Act, for
safeguarding the assets of the Company and for
preventing and detecting fraud and other irregularities;

(d) they have prepared the annual financial statements on
a going concern basis;

(e) they have laid down internal financial controls to be
followed by the Company and that such internal financial
controls are adequate and operating effectively; and

(f) they have devised proper systems to ensure compliance
with the provisions of all applicable laws and that such
systems are adequate and operating effectively.

SECRETARIAL STANDARDS

The Company has devised proper systems to ensure
compliance with the applicable provisions of Secretarial
Standards issued by the Institute of Company Secretaries
of India and that such systems are adequate and
operating effectively.

AUDITORS AND AUDITORS’ REPORT

Statutory Auditor

Pursuant to the provisions of Section 139 of the Act and
the Companies (Audit and Auditors) Rules, 2014 (including
any statutory modification(s) or re-enactment(s) thereof,
for the time being in force), M/s. Deloitte Haskins & Sells
LLP (Firm Registration No. 117366W/W-100018), Chartered
Accountants, the Statutory Auditors of the Company, were
appointed pursuant to the resolution passed by the Members
at the 50^th AGM of the Company held on 30 August, 2024, for
a term of 5 (five) consecutive years from the conclusion of
50^th AGM of the Company until the conclusion of the 55^th AGM
to be held in year 2029. As per the provisions of Section 139
of the Act, the appointment of Statutory Auditors is required
to be ratified by the Members at every AGM. However, in
accordance with the Companies Amendment Act, 2017,
enforced on 7 May, 2018 by the Ministry of Corporate Affairs,
the appointment of Statutory Auditors is not required to be
ratified at every AGM.

M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, the
Statutory Auditors of the Company have confirmed that they
are not disqualified from continuing as the Statutory Auditors
of the Company for financial year 2025-2026.

The Auditors' Report for financial year ended 31 March,
2025, is an unmodified one. However, pursuant to CARO
report, following are the adverse remarks stated in the
Auditor's Report:

- Delay in depositing Provident Fund for certain employees
during the year which was mainly due to their Aadhar
number not being linked to the Universal Account
Number (UAN). The Company is however in the process
of resolving the said issue so that dues can be deposited.

- The Company has a valid share certificate of 510 to
513 Shah Nahar property in its name, however the title
deeds of the said property were not traceable and the
Company is in the process of procuring a copy of the
same from the concerned statutory authority.

Cost Auditor

The Company is required to maintain cost records for certain
products as specified by the Central Government under
Section 148(1) of the Act and accordingly such accounts and
records are made and maintained in the prescribed manner.

Pursuant to the provisions of Section 148 of the Act and the
rules made thereunder read with notifications/ circulars
issued by the Ministry of Corporate Affairs from time-to-
time and as per the recommendation of the Audit Committee,
the Board of Directors at its meeting held on 29 May, 2024,
had re-appointed Mr. Suresh D. Shenoy, Cost Accountant
(Membership No. 8318), as the Cost Auditor of the Company
for financial year 2024-25 to conduct the audit of the cost
records of the Company. A resolution for ratification of the
fees payable to the Cost Auditor is included in the Notice of
AGM for seeking approval of Members. The Cost Audit Report
will be filed within the period stipulated under the Act.

Secretarial Auditor

Pursuant to the provisions of Section 204 of the Act read
with the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014, the Board of Directors
had appointed M/s Manish Ghia & Associates, Practicing
Company Secretaries, (Membership No. F6252, COP No.
3531) to conduct Secretarial Audit of the Company for
financial year 2024-25. Secretarial Audit Report is annexed
to this Report as Annexure F. The said Report does not contain
any qualification, reservation or adverse remark.

ANNUAL RETURN

The Annual Return of the Company in prescribed Form MGT-7
is available on the website of the Company at https://www.
alkemlabs.com/investors/annual-returns

RELATED PARTY TRANSACTIONS

All the Related Party Transactions entered into by the
Company during financial year 2024-25, were at arm's length
basis and in compliance with the applicable provisions of the
Act and the SEBI LODR Regulations and are in conformity with
the Company's Policy on Related Party Transactions.

The disclosure of material related party transactions entered
into by the Company during financial year 2024-25, as
required under Section 134(3)(h) of the Act read with Rule
8(2) of the Companies (Accounts) Rules, 2014 in Form AOC-2
is annexed to this Report as Annexure G. The Policy on Related
Party Transactions as approved by the Board of Directors is
posted on the Company's website at https://admin.alkemlabs.
com/uploads/Final Policy on Related Party Transactions
Feb 2025 fedbf7ca56.pdf

PARTICULARS OF LOANS/ GUARANTEES
GIVEN/ INVESTMENTS MADE AND SECURITIES
PROVIDED

The particulars of loans, guarantees, investments and
securities provided covered under the provisions of Section
186 of the Act have been disclosed in the notes to the financial
statements forming part of the Annual Report.

VIGIL MECHANISM / WHISTLE BLOWER POLICY

Pursuant to the provisions of Section 177(9) of the Act, the
Board of Directors of the Company have framed the Vigil
Mechanism / Whistle Blower Policy for employees and/
or volunteers of the Company. The said Policy encourages
to report any action or suspected action taken within the
Company that is illegal, fraudulent or in violation of any
adopted policy of the Company including reporting of
instances of leak or suspected leak of unpublished price
sensitive information. The Policy also provides access to
the Chairperson of the Audit Committee under certain
circumstances. The Whistle Blower Policy is posted on the
website of the Company at https://admin.alkemlabs.com/
uploads/Whistle Blower Policy new 5d094b8491.pdf

PREVENTION OF SEXUAL HARASSMENT AT
WORKPLACE

The Company has adopted a policy in line with the provisions
of Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013 and the Rules
made thereunder.

Internal Complaints Committees have been constituted
at Company's head office as well as at all the Company's
plants, depots and R&D centers to redress complaints
received on sexual harassment. During financial year
2024-25, the Company has not received any complaint of
sexual harassment.

DISCLOSURES UNDER THE ACT

Change in Nature of Business, if any:

During financial year 2024-25, there has been no change in
the nature of business of the Company.

Material Changes and Commitments affecting the
financial position of the Company:

There are no material changes and commitments, which
have occurred between the end of financial year and the date
of the Report which have affected the financial position of
the Company.

Significant and Material Orders:

The Company has not received any significant or material
orders passed by any regulatory authority, court or tribunal
which may impact the going concern status and Company's
operations in future.

Reporting of Frauds by Auditors:

During the year under review, there were no frauds reported
by Auditors under Section 143(12) of the Act.

Details on Insolvency and Bankruptcy Code:

During the year under review, no application has been made
by the Company under the Insolvency and Bankruptcy Code
and accordingly the requirement of disclosing the following
details are not applicable to the Company:

(i) t he details of application made or any proceeding
pending under the Insolvency and Bankruptcy Code,
2016 (31 of 2016) during the year alongwith their status
as at the end of the financial year; and

(ii) the details of difference between amount of the
valuation done at the time of onetime settlement and
the valuation done while taking loan from the Banks or
Financial Institutions along with the reasons thereof.

DETAILS ON INTERNAL FINANCIAL CONTROLS
RELATED TO FINANCIAL STATEMENTS

The Company has designed and implemented a process
driven framework for Internal Financial Controls (IFC) as
mandated under the Act. The Company's policies, guidelines
and procedures provide for adequate checks and balances
and are meant to ensure that all transactions are authorized,
recorded and reported correctly.

During the year under review, Internal Auditors of the
Company with the external audit consultants have reviewed
the effectiveness and efficiency of these systems and
procedures. As per the said assessment, Board is of the
view that the IFC were adequate and effective during the
financial year.

CONSERVATION OF ENERGY, TECHNOLOGY
ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO

The information on conservation of energy, technology
absorption and foreign exchange earnings and outgo as
stipulated under Section 134(3)(m) of the Act and the Rules
framed thereunder is annexed herewith as Annexure H to
this Report.

ACKNOWLEDGEMENT

Your Directors would like to express sincere gratitude to all
valuable stakeholders of the Company viz., the Central and
State Government Departments, organizations, agencies, our
customers, shareholders, dealers, vendors, banks, medical
fraternity, patients and other business associates for their
excellent support and co-operation extended by them during
the financial year under review.

The Board of Directors also places on record its appreciation
for the significant contribution made by the employees
of the Company through their dedication, hard work and
unstinted commitment.

For and on behalf of the Board
Alkem Laboratories Limited

Basudeo N. Singh

Executive Chairman
DIN: 00760310
Mumbai, 29 May, 2025